

Sinfonia Biotherapeutics to Present at BIO Investor Forum on October 17.

BOULDER, Colorado, Oct. 8, 2018 -- Sinfonia Biotherapeutics, Inc., an early-stage biotherapeutics company pioneering the development of bioreactor-delivered treatments for inherited and genetically-defined orphan neurodegenerative diseases, announced today that it will present at the BIO Investor Forum being held on October 17 – 18 at the Westin St. Francis Hotel in San Francisco, California. The company is delighted to be one of the early-stage companies selected to participate in the BIO Investor Forum in San Francisco. Presentation details are as follows:

Date: Wednesday, October 17
Time: 9:15 AM
Room: Elizabethan B, Westin St. Francis Hotel, San Francisco

About BIO Investor Forum 2018

The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings.

About Sinfonia Biotherapeutics, Inc.

Sinfonia Biotherapeutics, Inc. is an early-stage biotherapeutics company focused on developing bioreactor-delivered treatments for inherited and genetically-defined orphan neurodegenerative diseases. Just as cancer is composed of many different subtypes, we believe dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, we are developing life-changing biologic therapies that target familial dementia subtypes with underlying disease mechanisms that are genetically-defined. We are utilizing bioreactor-based cell therapy to deliver biologics directly to affected brain tissues. iProg, our breakthrough, first-in-class therapy with lead indication treatment for GRN-related frontotemporal dementia (FTD), has demonstrated promising preclinical proof of concept results in animal models. The company's headquarters are located in Boulder, Colorado, while research and development operations are located in Huddinge, Sweden.

Sinfonia Biotherapeutics, Inc. Contact:

Bob Blomquist
CEO
+1 (303) 786-8310
bob@blomquist-associates.com